|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
We propose that targeting the USP9x/SOX2 axis represents a novel strategy for the therapeutic of osteosarcoma and other SOX2 related cancers.
|
31605775 |
2020 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The requirement of Sox2 for osteosarcoma formation as well as for the survival of the tumor cells suggests that disruption of Sox2-initiated pathways could be an effective strategy for the treatment of osteosarcoma.
|
29743593 |
2018 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
How Sox2 modulated Wnt/β catenin signaling pathway in OS remained to be discussed.
|
29619662 |
2018 |
|
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Osteosarcoma CSCs express stem-related factors (Sox2, Oct4, CD133) and chemokine receptors and ligands (CXCR4, CXCL12) involved in tumor proliferation and self-renewal.
|
29305964 |
2018 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
It has been shown that induced expression of four stem cell factors (Oct4, Sox2, Klf4, and c-Myc) changes the phenotype of osteosarcoma and breast cancer cells to osteosarcoma stem cells and breast cancer stem cells, respectively.
|
29200954 |
2017 |
|
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Thus, Sox2 and YAP1 reinforce each others expression to maintain stemness and tumorigenicity in OSs, but the activity of MZF1 and GABP is essential for YAP1 transcription.Stem Cells 2017;35:2340-2350.
|
28905448 |
2017 |
|
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
LncRNA SOX2-OT positively regulated SOX2 expression in osteosarcoma cells and positively associated with SOX2 expression in osteosarcoma tissues.
|
28960757 |
2017 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
The present study established a novel association between miR‑336 and Sox‑2 in OS.
|
28440454 |
2017 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Cancer stem cells (CSCs) are responsible for the resistance of osteosarcoma to chemotherapy and OCT4, SOX2 and SSEA4 have been used to identify CSCs in osteosarcoma.
|
28934267 |
2017 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
As a direct regulator of Sox‑2, miR‑34a has been hypothesized to be greatly associated with the regulation of malignancies in osteosarcoma.
|
28260055 |
2017 |
|
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Aldefluor-positive populations were detected in all osteosarcoma cell lines and overexpress SOX2, but not KLF4.
|
26332365 |
2016 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Thus, Sox2 interferes with the tumour-suppressive Hippo pathway to maintain CSCs in osteosarcomas.
|
25832504 |
2015 |
|
Osteosarcoma
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Taken together, our data indicate that miR-126 functions as a tumor suppressor in OS, which exerts its activity by suppressing the expression of Sox2.
|
24384842 |
2013 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
Our data indicate that Sox2 is required for osteosarcoma cell self renewal, and that Sox2 antagonizes the pro-differentiation Wnt pathway that can in turn reduce Sox2 expression.
|
21927024 |
2012 |
|
Osteosarcoma
|
0.100 |
Biomarker
|
disease |
BEFREE |
TSSC3 was expressed at a low level in T-ICs, while overexpression of TSSC3 could efficiently downregulate the expression of stem cell markers Nanog, Oct4 and Sox2 in T-ICs and decrease the clone formation rate, as well as downregulate tumorigenesis in MThFOB1.19 cells, supporting a suppressive role for TSSC3 in OS T-ICs.
|
22610481 |
2012 |